Our Partners
Generation of High-Quality Antibodies/Peptides with High Diversity
Platform where wet lab and AI are integrated (Patented)
Over 1 billion proprietary biopharmaceutical data, obtained from our lab.
Our proprietary method and AI technology enable us to identify hidden valuable antibodies/peptides by predicting fundamental properties of biopharmaceuticals, e.g. affinity, specificity, phage growth bias in E. coli, immunogenicity, etc.
Models of Collaboration
Our core technologies
We perform directed evolution experiments such as phage display and mRNA/cDNA display, in our wet lab and collect big data via NGS.
Machine learning model is utilized to predict features of biopharmaceuticals, e.g. deep neural networks, transformers, generative models, etc.
Original machines for laboratory automation allow us to generate data quickly for developing machine learning models.
Team
Ryu Ogawa, Ph.D.
CEO/Co-founder
Satoshi Tamaki, Ph.D.
CSO
Natsumi Negishi
CFO
Kengo Miura
External director
Tatsuo Tsutsumi
External director
Hiroshi Abe
Statutory auditor
Koichi Takahashi, Ph.D.
Adviser